Type 2 diabetes mellitus (T2DM) is intrinsically connected to overweight and obesity. It is a complex metabolic disorder that predisposes patients to, and is associated with, cardiovascular disease. In addition to the triumvirate of core defects associated with T2DM (involvement of the pancreatic beta cell, the muscle, and the liver), other mechanisms including hyperglucagonemia, accelerated gastric emptying, and incretin deficiency/resistance are also involved. This has led to the development of incretin-based therapies, such as glucagon-like peptide–1 (GLP-1) receptor agonists and dipeptidyl peptidase–4 (DPP-4) inhibitors. These newer therapies have beneficial effects on glycosylated hemoglobin A1c (HbA1c) levels, weight, and pancreatic beta-cell function.

Hormonal deficiencies in T2DM are related to abnormalities in the secretion of amylin, glucagon, and incretin hormones. In clinical trials, GLP-1 receptor agonists reduced HbA1c levels, had beneficial effects on weight, and caused less hypoglycemia than insulin analogues.

Both GLP-1 receptor agonists and DPP-4 inhibitors improve pancreatic beta-cell function.

Incretin-based therapies have been incorporated into recently updated clinical guidelines for treatment of T2DM.

The prevalence of type 2 diabetes mellitus (T2DM) is increasing exponentially worldwide. According to the Centers for Disease Control and Prevention, more than 23 million Americans had diabetes in 2007. Globally, the prevalence of diabetes, of which T2DM accounts for 90% to 95% of cases, is expected to increase from 171 million in 2000 to 366 million in 2030. The National Health and Nutrition Examination Survey (NHANES) showed that about 66% of Americans were overweight or obese between 2003–2004. Data from a Swedish National Diabetes Register study showed both overweight and obesity as independent risk factors for cardiovascular disease (CVD) in patients with T2DM.

This article presents an overview of the evolving concepts of the pathophysiology of T2DM, with a focus on two new therapeutic classes: the glucagon-like peptide–1 (GLP-1) receptor agonists and the dipeptidyl peptidase–4 (DPP-4) inhibitors.

The American Association of Clinical Endocrinologists (AACE) describes T2DM as “a progressive, complex metabolic disorder characterized by coexisting defects of multiple organ sites including insulin resistance in muscle and adipose tissue, a progressive decline in pancreatic insulin secretion, unrestrained hepatic glucose production, and other hormonal deficiencies.” Other defects include accelerated gastric emptying in patients with T2DM, especially those who are obese or who have the disease for a long duration.

Hormonal deficiencies in T2DM are related to abnormalities in the secretion of the beta-cell hormone amylin, the alpha-cell hormone glucagon, and the incretin hormones GLP-1 and glucose-dependent insulinotrophic polypeptide (GIP). In addition to the triumvirate of core defects associated with T2DM (involvement of the pancreatic beta cell, muscle, and liver), other mechanisms of disease onset have been advanced, including accelerated lipolysis, hyperglucagonemia, and incretin deficiency/resistance. Also, the rate of basal hepatic glucose production is markedly increased in patients with T2DM, which is closely
INCRETIN-BASED THERAPIES: GLP-1 RECEPTOR AGONISTS AND DPP-4 INHIBITORS IN DEVELOPMENT

Exenatide is a GLP-1 receptor agonist that is resistant to DPP-4 degradation. Based on preclinical studies, exenatide, which shares a 53% amino acid sequence identity with human GLP-1, is approximately 5,500 times more potent than endogenous GLP-1 in glucose lowering.14,15 Among the acute actions of exenatide is glucose-dependent insulinotropism, the end result of which may be a reduced risk of hypoglycemia.16 This contrasts with insulin secretagogues (eg, sulfonylureas), which increase insulin secretion regardless of glucose concentrations.

Exenatide received US Food and Drug Administration (FDA) approval in 2005 and is indicated for the treatment of patients with T2DM.13,17 Exenatide is administered BID as a subcutaneous (SC) injection in doses of 5 or 10 μg within 1 hour before the two major meals of the day, which should be eaten about 6 hours apart.18

Approved in 2006, sitagliptin was the first DPP-4 inhibitor indicated for adjunctive therapy to lifestyle modifications for the treatment of patients with T2DM.17 The recommended dosage of oral sitagliptin is 100 mg QD. A single-tablet formulation of the combination of sitagliptin and metformin was approved by the FDA in 2007.19 Another DPP-4 inhibitor, saxagliptin, was approved in July 2009 for treatment of patients with T2DM either as monotherapy or in combination with metformin, sulfonylurea, or a thiazolidinedione (TZD).20 The DPP-4 inhibitor vildagliptin is approved in the European Union and Latin America but not in the United States. Vildagliptin is available as a 50- or 100-mg daily dosage; it has been recommended for use at 50 mg QD in combination with a sulfonylurea or at 50 mg BID with either metformin or a TZD.18

GLP-1 RECEPTOR AGONISTS AND DPP-4 INHIBITORS IN DEVELOPMENT

Exenatide is currently being evaluated as a once-weekly formulation.11,12 Compared with the BID formulation, exenatide once weekly has been shown to produce significantly greater improvements in glycemic control, with similar reductions in body weight and no increased risk of hypoglycemia.21

Also undergoing regulatory review is the partly DPP-4–resistant acylated GLP-1 receptor agonist liraglutide.23 Liraglutide, a human analogue GLP-1 receptor agonist, has 97% linear amino acid sequence homology to human GLP-1.23,24 Based on its prolonged degradation time and resulting 10- to 14-hour half-life, liraglutide is anticipated to be dosed once daily.13,25,26

Other GLP-1 receptor agonists and DPP-4 inhibitors are in varying stages of development.27 Albiglutide is a long-acting GLP-1 receptor agonist that is generated by the genetic fusion of a DPP-4–resistant GLP-1 to human albumin. Based on pharmacokinetic studies, albiglutide has a half-life of 6 to 8 days. AVE0010, an exendin-4–based GLP-1 receptor agonist, was shown in a 28-day T2DM clinical trial to have an affinity four times greater than native GLP-1 for the human GLP-1 receptor.27 Taspoglutide (R1583), a human analogue GLP-1 receptor agonist, was evaluated in three randomized, placebo-controlled studies as a GLP-1 receptor agonist. Alogliptin, a DPP-4 inhibitor currently in development, has been shown to be safe and effective in studies as monotherapy and in combination with other antidiabetes agents.28–30

CLINICAL TRIALS: GLP-1 RECEPTOR AGONISTS AND DPP-4 INHIBITORS

This section summarizes clinical trials of GLP-1 receptor agonists and DPP-4 inhibitors. The summary is based on literature published from 2005 to 2009 relevant to phase 3 or 4 T2DM clinical trials with currently available agents, or agents with pending new drug applications.

Table 1 summarizes the data on the effects of the GLP-1 receptor agonists on glucose lowering based on glycated hemoglobin (HbA1c) mean changes from baseline, body weight, and hypoglycemia. Eleven studies were identified for exenatide, including three pivotal trials,31–33 three insulin-comparator studies,34–36 one long-term study,37 one monotherapy study (a use for which it is not currently indicated),38 one head-to-head study with a DPP-4 inhibitor,39 and two studies with exenatide once weekly (which is currently investiga-
Five primary efficacy studies with liraglutide were also identified.\textsuperscript{21,22}\n
Table 2 summarizes the corresponding data for the DPP-4 inhibitors. Ten studies with sitagliptin were identified, including four monotherapy studies,\textsuperscript{42-45} one head-to-head study with a GLP-1 receptor agonist,\textsuperscript{39} and five studies in which sitagliptin was used in combination or as add-on therapy.\textsuperscript{46-50} Five saxagliptin studies are reviewed, including two in which saxagliptin was used in combination with metformin and one in combination with glyburide.\textsuperscript{51-53} Six studies with vildagliptin were reviewed,\textsuperscript{54-58} but no trials specific to the single-tablet formulation of sitagliptin plus metformin were identified.

**Table 1**

<table>
<thead>
<tr>
<th>Study</th>
<th>Study population/ duration of therapy</th>
<th>Study agents</th>
<th>HbA1c (mean △BL)</th>
<th>Weight (mean △BL)</th>
<th>Hypoglycemia</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EXENATIDE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DeFronzo 2005\textsuperscript{18}</td>
<td>Pivotal study in patients receiving MET N = 272/30 wk</td>
<td>E: 5 or 10 μg BID SC PL</td>
<td>E: −0.40% to −0.78% PL: +0.8% (P &lt; .002) E: −1.6 kg to −2.8 kg PL: −0.3 kg (P &lt; .001)</td>
<td>E vs PL: 5% vs 5%</td>
<td></td>
</tr>
<tr>
<td>Kendall 2005\textsuperscript{18}</td>
<td>Pivotal study in patients receiving MET and an SU N = 733/30 wk</td>
<td>E: 5 or 10 μg BID SC PL</td>
<td>E: −0.6% to −0.8% PL: +0.2% (P &lt; .0001) E: −1.6 kg PL: −0.9 kg (P &lt; .01)</td>
<td>E vs PL: 23% vs 13%</td>
<td></td>
</tr>
<tr>
<td>Zinman 2007\textsuperscript{18}</td>
<td>Pivotal study in patients receiving a TZD ± MET N = 233/16 wk</td>
<td>E: 10 μg BID SC PL</td>
<td>E: −0.89% PL: +0.09% (P &lt; .001) E: −1.75 kg PL: −0.2 kg (P &lt; .001)</td>
<td>E vs PL: 11% vs 7%</td>
<td></td>
</tr>
<tr>
<td>Barnett 2007\textsuperscript{18}</td>
<td>IN-comparator noninferiority study N = 138/2 16-wk trial periods</td>
<td>E: 10 μg BID SC IN GL: QT titrated to FSB &lt; 5.6 mmol/L</td>
<td>E: −1.36% IN GL: −1.36% (P &lt; .001) E: −2.0 kg to −2.2 kg IN GL: +1.0 kg to +2.3 kg</td>
<td>E vs IN GL: 15% vs 25%</td>
<td></td>
</tr>
<tr>
<td>Heine 2005\textsuperscript{18}</td>
<td>IN-comparator study in patients with HbA1c 7.0%–10.0% despite MET and SU N = 551/26 wk</td>
<td>E: 10 μg BID SC IN GL: QT titrated to FSB &lt; 5.6 mmol/L (100 mg/dl)</td>
<td>E: −1.11% IN GL: −1.11%</td>
<td>E vs IN GL: 7.3 vs 6.3 events/patient-yr</td>
<td></td>
</tr>
<tr>
<td>Nauck 2007\textsuperscript{18}</td>
<td>IN-comparator study N = 501/52 wk, while continuing with MET and SU</td>
<td>E: 5 μg BID SC for 4 wk, 10 μg thereafter Biplastic IN AS BID SC, titrated to optimal control</td>
<td>E: −1.04% IN AS: −0.89%</td>
<td>E vs IN AS: 17% vs 25%</td>
<td></td>
</tr>
<tr>
<td>Klonoff 2008\textsuperscript{18}</td>
<td>Long-term open-label study to assess glycemic control, CV risk, and hepatic injury markers N = 217 completed 3 yr of therapy, N = 151 completed 3.5 yr of therapy</td>
<td>E: 5 or 10 μg BID SC for 30 wk, then 5 μg BID SC for 4 wk, then 10 μg BID SC for &gt; 3 yr At 3 yr: E: −1.0% (P &lt; .0001) At 3.5 yr: E: −0.8% (P &lt; .0001) At 3.5 yr: E: −5.3 kg (P &lt; .001)</td>
<td>Hypoglycemia with E, usually mild to moderate: 40%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moretto 2008\textsuperscript{18}</td>
<td>Monotherapy study N = 232/24 wk</td>
<td>E: 5 or 10 μg BID SC PL</td>
<td>E: −0.7% to −0.9% PL: −0.2% E: −2.8 kg to −3.1 kg PL: −1.4 kg</td>
<td>E vs PL: 4% vs 1%</td>
<td></td>
</tr>
<tr>
<td>DeFronzo 2008\textsuperscript{18}</td>
<td>First clinical head-to-head study between a GLP-1 receptor agonist and a DPP-4 inhibitor, in patients receiving MET N = 61/crossover study with two treatment periods of 2 wk preceded by 1-wk PL lead-in and no interval washout</td>
<td>E: 5 μg BID SC for 1 wk, then 10 μg BID SC for 1 wk ST: 100 mg QD PO for 2 wk</td>
<td>E: −15 mg/dl (FPG) ST: −19 mg/dl (FPG) (P = .3234)</td>
<td>E: −0.8 kg ST: −0.3 kg (P = .0056) No major hypoglycemic events with E or ST</td>
<td></td>
</tr>
</tbody>
</table>

Table continues on next page
Effects on weight with liraglutide varied from a mean to once weekly resulted in mean weight reductions of up to weight compared with the insulin analogues, which led to weight gain.

**Hypoglycemia.** Patients receiving exenatide experienced lower rates of hypoglycemia (up to 17%) than patients treated with either insulin glargine or insulin aspart (~25%). The rate of hypoglycemia with exenatide is comparable to that seen with metformin (up to 21%) in a systematic review of oral antidiabetes agents conducted by the Agency for Healthcare Research and

**TABLE 1 (continued)**

**Effects of the GLP-1 receptor agonists on HbA1c, weight, and hypoglycemia in patients with T2DM**

<table>
<thead>
<tr>
<th>Study</th>
<th>Study population/ duration of therapy</th>
<th>Study agents</th>
<th>HbA1c (mean ∆BL)</th>
<th>Weight (mean ∆BL)</th>
<th>Hypoglycemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kim 2007$^{22}$</td>
<td>Pilot study of E once weekly$^a$ N = 45/15 wk</td>
<td>E: 0.8 or 2.0 mg QW SC PL</td>
<td>E QW: −1.4% to −1.7% PL: +0.4% (P &lt; .0001)</td>
<td>E QW: −3.8 kg PL: 0 kg (P &lt; .05)</td>
<td>E QW vs PL: 25% vs 0%</td>
</tr>
<tr>
<td>Drucker 2008$^{33}$</td>
<td>DURATION-1 study: E QW$^a$ vs E BID N = 295/30 wk</td>
<td>E: 2 mg QW SC E: 10 μg BID SC</td>
<td>E QW: −1.9% E BID: −1.5% (P = .023)</td>
<td>E QW: −3.7 kg E BID: −3.6 kg (P = .89)</td>
<td>No major hypoglycemic events with E QW or E BID</td>
</tr>
</tbody>
</table>

**LIRAGLUTIDE$^a$**

| Vilbess 2007$^{33}$ | Placebo-controlled study N = 165/14 wk | L: 0.65, 1.25, or 1.90 mg QD SC PL | L: −0.98% to −1.45% PL: +0.29% (P < .0001) | L: −2.99 kg PL: −1.78 kg (P = .390 for L 1.90 mg) | No major or minor hypoglycemic events with L or PL |
| Seino 2008$^{33}$ | Dose-response study in Japanese patients treated with diet ± oral agents N = 226/14 wk | L: 0.1, 0.3, 0.6, or 0.9 mg QD SC PL | L: −0.72% to −1.67% PL: +0.09% | L: −0.48 kg to +0.13 kg PL: −0.95 kg | No major or minor hypoglycemic events with L or PL |
| Nauck 2009$^a$ | LEAD-2 study N = 1,091/26 wk, in combination with MET and in patients previously treated with oral agents | L: 0.6, 1.2, or 1.8 mg/d QD SC G: 4 mg QD PO PL | L: −0.7% to −1.0% G: −1.0% PL: +0.1% | L: −1.8 kg to −2.8 kg G: +1.0 kg PL: −1.5 kg (P < .0001 vs G; P < .01 vs PL) | No major hypoglycemic events with L, G, or PL |
| Garber 2009$^{35}$ | LEAD-3-Mono N = 746/52 wk, as monotherapy | L: 1.2 or 1.8 mg QD SC G: 8 mg QD PO | L: −0.84% to −1.14% G: −0.51% (P < .001) | L: −2.0 kg to −2.5 kg G: +1.0 kg | No major hypoglycemic events with L or G |
| Marre 2009$^{33}$ | LEAD-1 SU N = 1,041/26 wk, added to SU (G) 2–4 mg/d | L: 0.6, 1.2, or 1.8 mg QD SC + R PL R = L PL + R 4 mg/d PL = L PL + R PL | L: 1.2 mg or 1.8 mg: −1.1% (P < .0001) R: −0.4% (P < .0001) PL: +0.2% | L: 1.2 mg or 1.8 mg: −0.2 kg to +0.7 kg R: +2.1 kg PL: +0.1 kg | Minor hypoglycemia: < 10% for all |

* Both the parenterally administered once-weekly formulation of exenatide and QD liraglutide are under regulatory review with pending new drug applications; exenatide was granted US Food and Drug Administration approval in 2005 and is currently available only as a BID formulation.

**AS = aspartate; BID = twice daily; CV = cardiovascular; DPP-4 = dipeptidyl peptidase-4; DURATION-1 = Diabetes Therapy Utilization: Researching Changes in A1C, Weight and Other Factors Through Intervention with Exenatide Once Weekly; E = exenatide; FBG = fasting blood glucose; FPG = fasting plasma glucose; FSG = fasting serum glucose; G = glimepiride; GL = glargine; GLP-1 = glucagon-like peptide–1; HbA1c = glycosylated hemoglobin; IN = insulin; L = liraglutide; LEAD = Liraglutide Effects and Actions in Diabetes; MET = metformin; PL = placebo; PO = by mouth; QD = once daily; QW = once weekly; R = rosiglitazone; SC = subcutaneous; SU = sulfonylurea; T2DM = type 2 diabetes mellitus; TID = thiazolidinedione; ∆BL = change from baseline.

**Weight reduction with GLP-1 receptor agonists.** In addition to effective glucose lowering, the GLP-1 receptor agonists, particularly exendin-4 agonists, produced beneficial effects on weight (Table 1). Exenatide BID elicited mean weight reductions up to −3.6 kg at 30 weeks$^{21,31,32}$ and −5.3 kg at 35 years.$^{37}$ Exenatide once weekly resulted in mean weight reductions of up to −3.8 kg at 15 weeks$^{22}$ and −3.7 kg at 30 weeks.$^{21}$ Effects on weight with liraglutide varied from a mean reduction of up to −2.99 kg to a slight gain of up to +0.13 kg at 14 weeks$^{40,41}$ and with weight loss of up to −2.8 kg at 26 weeks$^{23,26}$ and up to −2.5 kg at 52 weeks.$^{25}$ In this review, only exenatide has been assessed in insulin-comparator studies, where it was shown to reduce weight compared with the insulin analogues, which led to weight gain.$^{14,36}$

In this review, only exenatide has been assessed in insulin-comparator studies, where it was shown to reduce weight compared with the insulin analogues, which led to weight gain.$^{14,36}$

In this review, only exenatide has been assessed in insulin-comparator studies, where it was shown to reduce weight compared with the insulin analogues, which led to weight gain.$^{14,36}$

It is important to note that the results of this review are not directly comparable to those from clinical trials, as they are based on post hoc analyses of data from various studies.
### TABLE 2
Effects of DPP-4 inhibitors on HbA1c, weight, and hypoglycemia in patients with T2DM

<table>
<thead>
<tr>
<th>Study</th>
<th>Study population/ duration of therapy</th>
<th>Study agents</th>
<th>HbA1c (mean ΔBL)</th>
<th>Weight (mean ΔBL)</th>
<th>Hypoglycemia</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SITAGLIPTIN</strong>&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aschner 2006&lt;sup&gt;12&lt;/sup&gt;</td>
<td>Monotherapy N = 741/24 wk</td>
<td>ST: 100 or 200 mg QD PO PL</td>
<td>ST: −0.61% to −0.76% PL: +0.18% (P ≤ .001 vs PL)</td>
<td>ST: −0.1 kg to −0.2 kg (neutral effect) PL: −1.1 kg (P &lt; .001)</td>
<td>ST vs PL: 1% vs 1%</td>
</tr>
<tr>
<td>Raz 2006&lt;sup&gt;44&lt;/sup&gt;</td>
<td>Monotherapy N = 521/18 wk, with inadequate glycemic control on diet and exercise</td>
<td>ST: 100 or 200 mg QD PO PL</td>
<td>ST: −0.36% to −0.48% PL: +0.12%</td>
<td>ST: −0.2 kg to −0.6 kg PL: −0.7 kg</td>
<td>ST vs PL: 1% vs 0%</td>
</tr>
<tr>
<td>Scott 2007&lt;sup&gt;75&lt;/sup&gt;</td>
<td>Monotherapy N = 743/12 wk</td>
<td>ST: 5, 12.5, 25, or 50 mg BID PO GLP: 5 mg/d PO (electively titrated up to 20 mg/d) PL</td>
<td>ST: −0.15% to −0.54% GLP: −0.76% PL: +0.23%</td>
<td>ST: +0.1 kg to +0.4 kg (relative to PL) GLP: +1.3 kg (relative to PL)</td>
<td>ST vs GLP vs PL: 2% vs 17% vs 2%</td>
</tr>
<tr>
<td><strong>Nonaka</strong> 2008&lt;sup&gt;33&lt;/sup&gt;</td>
<td>Monotherapy, in Japanese patients N = 151/12 wk</td>
<td>ST: 100 mg QD PO PL</td>
<td>ST: −0.65% PL: +0.41% (P &lt; .001)</td>
<td>ST: −0.1 kg PL: −0.7 kg</td>
<td>No hypoglycemic episodes with ST or PL</td>
</tr>
<tr>
<td>DeFronzo 2008&lt;sup&gt;19&lt;/sup&gt;</td>
<td>First clinical head-to-head study between a DPP-4 inhibitor and a GLP-1 receptor agonist, in MET-treated patients N = 61/crossover study with two treatment periods of 2 wk preceded by 1-wk PL lead-in and no interval washout</td>
<td>ST: 100 mg QD PO for 2 wk E: 5 μg BID SC for 1 wk, then 10 μg BID SC for 1 wk</td>
<td>ST: −19 mg/dL (FPG) E: −15 mg/dL (FPG) (P = .3234)</td>
<td>ST: −0.3 kg E: −0.8 kg (P = .0056)</td>
<td>No major hypoglycemic events with ST or E</td>
</tr>
<tr>
<td>Charbonnel 2006&lt;sup&gt;46&lt;/sup&gt;</td>
<td>N = 701/24 wk, added to ongoing MET therapy</td>
<td>ST: 100 mg QD PO PL</td>
<td>ST: −0.67% PL: −0.02% (P &lt; .001)</td>
<td>ST: −0.6 kg to −0.7 kg (both P &lt; .05 vs BL, but P = .835 between groups)</td>
<td>ST vs PL: 1% vs 2%</td>
</tr>
<tr>
<td>Rosenstock 2006&lt;sup&gt;61&lt;/sup&gt;</td>
<td>N = 353/24 wk; added to ongoing TZD (pioglitazone) therapy</td>
<td>ST: 100 mg QD PO PL</td>
<td>ST: −0.85% PL: −0.15%</td>
<td>ST: +1.8 kg PL: +1.5 kg (P = NS)</td>
<td>ST vs PL: 1% vs 0%</td>
</tr>
<tr>
<td>Hermansen 2007&lt;sup&gt;77&lt;/sup&gt;</td>
<td>In patients inadequately controlled with G or G + MET N = 441/24 wk</td>
<td>ST: 100 mg QD PO PL</td>
<td>ST: −0.45% PL: +0.28% (P &lt; .001)</td>
<td>ST: +0.8 kg PL: −0.4 kg (P &lt; .001)</td>
<td>ST vs PL: 12% vs 2%</td>
</tr>
<tr>
<td>Nauck 2007&lt;sup&gt;78&lt;/sup&gt;</td>
<td>In patients inadequately controlled with MET N = 1,172/52 wk</td>
<td>ST: 100 mg QD PO MET ≥ 1,500 mg/d GLP: 5 mg/d (titrated to 20 mg/d) MET ≥ 1,500 mg/d</td>
<td>ST: −0.67% GLP: −0.67%</td>
<td>ST: −1.5 kg GLP: +1.1 kg</td>
<td>ST vs GLP: 5% vs 32%</td>
</tr>
<tr>
<td>Raz 2008&lt;sup&gt;48&lt;/sup&gt;</td>
<td>Added to ongoing MET N = 190/30 wk</td>
<td>ST: 100 mg QD PO MET ≥ 1,500 mg/d PL + MET ≥ 1,500 mg/d</td>
<td>ST: −1.0% PL: 0.0%</td>
<td>ST: −0.5 kg PL: −0.5 kg</td>
<td>ST vs PL: 1% vs 0%</td>
</tr>
</tbody>
</table>

| **SAXAGLIPTIN**<sup>a</sup> | | | | | |
| Chacra 2007<sup>51</sup> | Patients inadequately controlled with sulfonylurea N = 769/24 wk | SX: 2.5 or 5 mg/d GLY: 7.5 mg/d PL + GLY: 10 mg/d | SX: −0.54% to −0.64% GLY: +0.08% (P = .0001) | SX: +0.7 kg to +0.8 kg GLY: +0.3 kg | SX: 13.3% to 14.6% GLY: 10.1% |
| DeFronzo 2007<sup>52</sup> | Patients inadequately controlled with MET N = 743/24 wk | SX: 2.5, 5, or 10 mg/d MET PL + MET | SX: −0.59% to −0.69% MET: +0.13% (P < .0001) | SX: −0.53 kg to −1.43 kg MET: −0.92 kg | Table continues on next page |
### TABLE 2 (continued)

Effects of DPP-4 inhibitors on HbA1c, weight, and hypoglycemia in patients with T2DM

<table>
<thead>
<tr>
<th>Study</th>
<th>Study population/ duration of therapy</th>
<th>Study agents</th>
<th>HbA1c (mean ΔBL)</th>
<th>Weight (mean ΔBL)</th>
<th>Hypoglycemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jadzinsky53</td>
<td>Treatment-naïve patients N = 1306/24 wk</td>
<td>SX: 5 or 10 mg/d + MET 500 mg/d</td>
<td>SX + MET: −2.5%</td>
<td>SX: −1.4 kg to −1.8 kg</td>
<td>≤ 2% in all groups</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SX: 10 mg + PL MET: 500 mg/d (MET titrated up to 2,000 mg/d)</td>
<td>SX: −1.7%</td>
<td>SX: −1.1 kg</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(P &lt; .0001 vs monotherapy)</td>
<td>MET: −2.0%</td>
<td>MET: −1.6 kg</td>
<td></td>
</tr>
<tr>
<td>Rosenstock54</td>
<td>Treatment-naïve patients N = 401/24 wk</td>
<td>SX: 2.5, 5, or 10 mg/d PL</td>
<td>SX: −0.43%</td>
<td>SX: −0.1 kg to −1.2 kg</td>
<td>None confirmed</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PL</td>
<td>+0.19%</td>
<td>PL: −1.4 kg</td>
<td></td>
</tr>
<tr>
<td>Rosenstock55</td>
<td>Dose-ranging trial Low dose: Adjusted mean Δ</td>
<td>Not significant</td>
<td>Two mild cases in high-dose cohort</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>N = 338/12 wk (low-dose) N = 85/6 wk (high-dose)</td>
<td>SX: 2.5, 5, 10, 20, 40 mg/d or PL</td>
<td>Low dose: SX: −0.45%</td>
<td>PL: −0.27%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>High dose: SX: 100 mg/d or PL</td>
<td>(P &lt; .0001)</td>
<td></td>
</tr>
<tr>
<td>VILDAGLIPTIN7</td>
<td>Drug-naïve patients V: 50 mg QD PO</td>
<td>V: 0.8% to −0.9%</td>
<td>V: −0.3 kg to −1.8 kg</td>
<td>No hypoglycemic events with V 50 mg BID or PL; one hypoglycemic event for two patients on V 50 mg QD and one patient on V 100 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N = 632/24 wk</td>
<td>V: 0.5 kg to −1.4 kg</td>
<td>PL: −1.4 kg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pan</td>
<td>Drug-naïve patients N = 661/24 wk</td>
<td>V: 100 mg/d, given as 50 mg BID PO</td>
<td>V: −1.4%</td>
<td>V: −0.4 kg</td>
<td>No hypoglycemic events with V or A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A: Up to 300 mg/d, given TID PO</td>
<td>A: −1.3%</td>
<td>A: −1.7 kg</td>
<td></td>
</tr>
<tr>
<td>Pi-Sunyer</td>
<td>Drug-naïve patients N = 354/24 wk</td>
<td>V: 50 mg QD PO</td>
<td>V: −0.5% to −0.8%</td>
<td>V: −0.0 kg to −0.4 kg</td>
<td>No confirmed hypoglycemia reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>V: 50 mg BID PO</td>
<td>PL: 0.0</td>
<td>PL: −1.4 kg</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>V: 100 mg QD PO PL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schweizer</td>
<td>Drug-naïve patients with baseline HbA1c 7.5% to 11.0% N = 780/52 wk</td>
<td>V: 100 mg QD PO MET titrated to 2,000 mg QD PO</td>
<td>V: −1.0%</td>
<td>V: +0.3 kg</td>
<td>V vs MET &lt; 1% for each group</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MET: −1.4% (P &lt; .001)</td>
<td>MET: −1.9 kg</td>
<td></td>
</tr>
<tr>
<td>Garber</td>
<td>Add-on to TZD (pioglitazone) therapy N = 463/24 wk</td>
<td>V: 50 mg QD PO</td>
<td>V: −0.8% to −1.0%</td>
<td>V: +0.1 kg to +1.3 kg</td>
<td>No severe hypoglycemic events reported with V or PL</td>
</tr>
<tr>
<td>20077</td>
<td></td>
<td>V: 100 mg QD PO PL</td>
<td>PL: −0.3%</td>
<td>Relative to PL PL: +1.4 kg</td>
<td></td>
</tr>
<tr>
<td>Göke</td>
<td>N = 463/52-wk extension of a previously published, multicenter, randomized, parallel-group study (Schweizer 200715)</td>
<td>V: 100 mg QD PO MET: 2,000 mg QD PO</td>
<td>V: −1.0%</td>
<td>V: +0.5 kg</td>
<td>Only one confirmed hypoglycemic event reported with V</td>
</tr>
<tr>
<td>200814</td>
<td></td>
<td></td>
<td>MET: −1.5% (P &lt; .001)</td>
<td>MET: −2.5 kg</td>
<td></td>
</tr>
</tbody>
</table>

---

* The orally administered sitagliptin was granted US Food and Drug Administration (FDA) approval in 2006; a single-tablet formulation of the combination of sitagliptin and metformin gained US FDA approval in 2007. Saxagliptin was approved by the FDA in 2009. Although used in Latin America and the European Union, vildagliptin has yet to receive regulatory approval in the United States.8

A = acarbose; BID = twice daily; BL = baseline; DPP-4 = dipeptidyl peptidase-4; E = exenatide; FPG = fasting plasma glucose; G = glimepiride; GLP = glipizide; GLP-1 = glucagon-like peptide-1; GLY = glyburide; HbA1c = glycosylated hemoglobin; MET = metformin; PL = placebo; PO = by mouth; QD = once daily; SC = subcutaneous; ST = sitagliptin; SX = saxagliptin; TID = three times daily; T2DM = type 2 diabetes mellitus; TZD = thiazolidinedione; V = vildagliptin; ΔBL = change from baseline.
Quality. No major hypoglycemic events were reported in the liraglutide studies reviewed. The incidence of hypoglycemia reported with DPP-4 inhibitors (Table 2) is also low (2% or less in most studies). The glucose-dependent mechanisms of the incretin-based therapies minimizes the risk of hypoglycemia.

**DPP-4 inhibitors and sustained HbA1c reduction.** The effects of the DPP-4 inhibitors on HbA1c and weight, either as monotherapy or in combination with other agents, were evaluated in studies ranging in duration from 12 to 52 weeks (Table 2). No studies were identified that compared the glycemic control effects of DPP-4 inhibitors and insulin analogues. Sitagliptin led to a mean reduction in HbA1c from baseline of up to −0.65% at 12 weeks, 0.67% to −0.38% at 18 weeks, up to −0.85% at 24 weeks, up to −1.0% at 30 weeks, and up to −0.67% at 52 weeks.

Saxagliptin mean reductions in HbA1c ranged from −0.43% to −1.17%. Data from four 24-week T2DM studies showed vildagliptin reducing HbA1c up to −1.4% at 24 weeks, with the greatest reduction in a study that involved drug-naïve patients with a relatively short duration of disease (mean, 1.2 years). Reductions in HbA1c of −1.0% were sustained in a 52-week study and its 52-week extension.

**DPP-4 inhibitors: weight neutral.** The DPP-4 inhibitors appear to have a weight-neutral effect (Table 2). The effects of sitagliptin on weight ranged from a loss of −1.5 kg at 52 weeks to a gain of +1.8 kg at 24 weeks. Two saxagliptin studies showed varying effects on weight ranging from a loss of up to −1.8 kg from baseline to a gain of up to +1.3 kg relative to placebo, both at 24 weeks.

**Potential for CV risk reduction**

Potentially beneficial effects on CV risk factors, including blood pressure (ie, reduction) and lipid concentrations (ie, differential effects on low-density lipoprotein and high-density lipoprotein cholesterol), were identified in seven GLP-1 receptor studies—three with exenatide (two with exenatide BID, 0.74% [95% confidence interval, −0.13% to −0.81%] for GLP-1 receptor agonists and −0.74% [95% CI, −0.85% to −0.62%] for DPP-4 inhibitors) and were noninferior to other antidiabetes agents. Treatment with a GLP-1 receptor agonist (ie, exenatide) caused weight loss (−1.4 kg and −4.8 kg vs placebo and insulin, respectively) while DPP-4 inhibitors (ie, sitagliptin, vildagliptin) were weight neutral.

**Adverse effects**

Exenatide has shown effects on hepatic injury markers (ie, improvement in alanine and aspartate aminotransferases) for up to 3.5 years of treatment. For the GLP-1 receptor agonist and DPP-4 inhibitor studies reviewed, the adverse events were generally mild and included nausea and vomiting, nasopharyngitis, and mild hypoglycemia.

**Meta-analysis conclusions**

The published clinical trial data presented in this review expand the body of evidence on the safety and efficacy of incretin-based therapy in patients with T2DM. These data include the results of a meta-analysis by Amor et al, which examined randomized controlled trials of 12 weeks’ or longer duration that compared incretin-based therapy with placebo or other diabetes medications and reported HbA1c changes in adults with T2DM. The meta-analysis showed that incretin-based therapies reduced HbA1c more than placebo (weighted mean difference, −0.97% [95% confidence interval, −1.13% to −0.81%] for GLP-1 receptor agonists and −0.74% [95% CI, −0.85% to −0.62%] for DPP-4 inhibitors) and were noninferior to other antidiabetes agents. Treatment with a GLP-1 receptor agonist (ie, exenatide) caused weight loss (−1.4 kg and −4.8 kg vs placebo and insulin, respectively) while DPP-4 inhibitors (ie, sitagliptin, vildagliptin) were weight neutral.

**Beta-cell function**

Evidence regarding the effects of incretin-based therapies, particularly the exendin-4 GLP-1 receptor agonists, on beta-cell function in patients with T2DM continues to accumulate. When assessing long-term (1 year) exenatide treatment in patients with T2DM, a trial (n = 69) comparing exenatide with the basal insu-
lin analogue insulin glargine showed that exenatide and insulin glargine resulted in similar reductions in HbA1c (−0.8% vs −0.7%; P = .55). However, exenatide significantly reduced body weight while insulin glargine resulted in weight gain (−3.6 kg vs +1.0 kg; P < .0001). In terms of beta-cell function, arginine-stimulated C-peptide secretion during hyperglycemia increased 2.46-fold from baseline after 52 weeks of exenatide treatment compared with 1.31-fold with insulin glargine treatment (P < .0001).

With respect to the direct beta-cell effects of liraglutide, a preclinical study reported that liraglutide improved glucose homeostasis in marginal mass islet transplantation in diabetic mice. In this study, liraglutide was shown, in a mouse model, to reduce the time to normoglycemia after islet cell transplantation (median time, 1 vs 72.5 days; P < .0001). The effects of liraglutide on beta-cell function also were assessed in 13 patients with T2DM. After 7 days of treatment, liraglutide improved beta-cell function, which was associated with improvement in glucose concentration. Liraglutide improved potentiation of insulin secretion during the first meal, owing in part to restoration of the potentiation peak (which is markedly blunted in T2DM), in a phenomenon similar to that observed with exenatide.

Beneficial effects on beta-cell function have also been reported with DPP-4 inhibitors. In a model-based analysis of patients with T2DM, it was shown that vildagliptin improved basal, static, and dynamic responsiveness of pancreatic beta cells to glucose. The results were observed when vildagliptin was administered both as an add-on to metformin therapy and as monotherapy. A 52-week, double-blind, randomized, parallel-group study compared vildagliptin 50 mg/day and placebo in 306 patients with T2DM and mild hyperglycemia (HbA1c, 6.2% to 7.5%). Vildagliptin was shown to significantly increase fasting insulin secretory tone, glucose sensitivity, and rate sensitivity, all of which are aspects of beta-cell function.

Summary
Based on the ability of incretin-based therapies to address various disease mechanisms, including beta-cell defects (ie, hyperglycemia), hormone-related abnormalities (ie, hyperglycagonegima, incretin deficiency/resistance), and accelerated gastric emptying (especially with GLP-1 receptor agonists); their favorable effects on weight (reduction with GLP-1 receptor agonists and neutral with DPP-4 inhibitors); their beneficial effects on CV risk factors; and their good safety profile (ie, hypoglycemia risk comparable with metformin), these agents could be considered therapeutic advances for the treatment of patients with T2DM.

INCRETIN-BASED THERAPIES IN GUIDELINES AND ALGORITHMS

The 2007 AACE medical guidelines for clinical practice for the management of diabetes recognized the place of the incretin-based therapies and included them among the pharmacologic options. Exenatide was specifically recommended for combination therapy with metformin, a sulfonylurea (secretagogue), a sulfonylurea plus metformin, or a TZD. Sitagliptin was recommended for use as monotherapy or in combination with metformin or a TZD.

In 2009, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes convened a consensus panel to produce an algorithm for the initiation and adjustment of therapy for patients with T2DM. In this algorithm, GLP-1 receptor agonists were considered appropriate in certain clinical scenarios (eg, when hypoglycemia was an issue or weight loss was a major consideration during treatment). However, the groups also noted a need for more data on long-term safety and the cost of treatment with incretin-based therapies.

The AACE and the American College of Endocrinology recently developed “road maps” for managing patients with T2DM. In patients with T2DM who are naïve to therapy, DPP-4 inhibitors are among the recommended first options when the initial HbA1c is 6.0% to 7.0% and as a combination therapy component when HbA1c reaches 7.0% to 9.0%. In patients who have already received monotherapy for 2 to 3 months and whose HbA1c is 6.5% to 8.5%, treatment options include combination therapy with a DPP-4 inhibitor and metformin or a TZD. Another option includes the initiation of treatment with a GLP-1 receptor agonist in combination with a TZD, with metformin or a sulfonylurea, or with metformin and a sulfonylurea.

The role of GLP-1 receptor agonist therapies and their incorporation into T2DM treatment algorithms was noted at the 2008 annual meeting of the ADA. In the Banting lecture, Ralph A. DeFronzo, MD, advocated the early use of triple-drug therapy with metformin, exenatide, and a TZD in the management of patients with T2DM.

CONCLUSION
T2DM, which is linked to weight gain and obesity, is a complex disease that predisposes patients to and is associated with CVD. A better understanding and appreciation of the role of the incretin system in the pathogenesis of T2DM has led to the development of incretin-based therapies, such as the GLP-1 receptor agonists and DPP-4 inhibitors. As more experimental and clinical evidence becomes available, subtle nuances are emerging that distinguish the roles of these two therapeutic classes.
DISCLOSURES

Dr. Davidson reported that he has received grant support from Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, MannKind Corporation, Novo Nordisk, Pfizer Inc., and Sanofi-Aventis; consulting/advisory fees from AstraZeneca, Boehringer ingelheim GmbH, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genexer Biotechnology Corporation, Johnson & Johnson, Novo Nordisk, and Takeda Pharmaceutical Company Limited; and speakers’ bureau fees from Eli Lilly and Company, Novo Nordisk, and Takeda Pharmaceutical Company Limited. He reported that he has stock ownership interest in Eli Lilly and Company, Genexer Biotechnology Corporation, GlaxoSmithKline, and Pfizer, Inc., managed by Royal Alliance Associates, Inc. Dr. Davidsen reported that he received no honorarium for writing this article.

Dr. Davidson reported that he wrote this article and received no assistance with content development from unnamed contributors. He reported that BlueSpark Healthcare Communications, a medical communications company, assisted with preliminary literature searches, reference verification, proofreading for grammar and style, table and figure rendering based on author instructions, copyright permission requests, and identification of topical overlap with other manuscripts in this supplement.

REFERENCES

Abstract 477-P.


Correspondence: Jaime A. Davidson, MD, 7777 Forest Lane, Suite C204, Dallas, TX 75230; davidsonmd@sbcglobal.net